Everolimus-coated balloon compared with paclitaxel-coated balloons for peripheral arterial disease in the leg
Compares an everolimus-coated balloon with paclitaxel-coated balloons in adults with narrowed leg arteries.
Key facts
- Who runs it
- Cook Research Incorporated
- Where
- Bay City, Camden, Dallas, Davenport, Gainesville, Greenville, Houston, Humble, Jacksonville, Lebanon, Long Beach, Miami, New Haven, Tupelo, and Washington D.C., United StatesSee the 15 sites
- Trial code
- Registry title
- EVERO Drug-coated Balloon (DCB) Randomized Trial
- Status
- Recruiting
- People taking part
- 410 people, planned
- Started
- 17 Apr 2026
- Expected to end
- Oct 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Evero DCB
- Paclitaxel DCB
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with peripheral arterial disease (narrowed leg arteries) in the thigh or knee artery. It compares an everolimus-coated balloon with paclitaxel-coated balloons.
- Age
- 18 Years and older
- Sex
- All sexes
- Disease stage
- Peripheral arterial disease with Rutherford classification 2 - 4. The narrowing is new or has come back (no stent there), in the superficial femoral artery, the popliteal artery (P1 or P2), or both.
- Earlier treatment
- The treated narrowing must not have a stent in it.
Main reasons for not taking part
- Life expectancy of 12 months or less, as judged by the study doctor
- Pregnant, breastfeeding, or planning pregnancy within 12 months, or unwilling to use contraception for 12 months
- Unable or unwilling to give informed consent
- Unable or unwilling to follow the visit schedule
- Taking part in another drug or device study, unless at least 30 days past its primary endpoint
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Documented PAD with Rutherford classification 2 - 4; and
- De novo or restenotic (non-stented) target lesion located in the native superficial femoral artery (SFA), popliteal artery (P1 or P2), or both native SFA and popliteal arteries
Who cannot take part
- Simultaneously participating in another investigational drug or device study unless the patient is at least 30 days beyond the primary endpoint of any previous study
- Less than 18 years old
- General Exclusion Criteria
- Inability or refusal to give informed consent by the patient or legally authorized representative
- Life expectancy ≤ 12 months, per investigator assessment
- Pregnant (or if absence of pregnancy is not verified by negative pregnancy test within 7 days of planned procedure), lactating, planning to become pregnant within 12 months of the planned procedure, or unwilling to use contraception for 12 months following the planned procedure
- Unable or unwilling to comply with the follow-up schedule; or
Where in United States
- McLaren Bay Region HospitalBay City, United StatesContact: Noah ShieldsTaking people
- Cooper University HospitalCamden, United StatesContact: Noah ShieldsTaking people
- University of Texas, SouthwesternDallas, United StatesContact: Noah ShieldsTaking people
- Midwest Cardiovascular Research FoundationDavenport, United StatesContact: Noah ShieldsTaking people
- The Cardiac and Vascular InstituteGainesville, United StatesContact: Noah ShieldsTaking people
- Prisma Health MemorialGreenville, United StatesContact: Noah ShieldsTaking people
- Houston Methodist HospitalHouston, United StatesContact: Noah ShieldsTaking people
- Vital Heart and VeinHumble, United StatesContact: Noah ShieldsTaking people
- First Coast Cardiovascular InstituteJacksonville, United StatesContact: Noah ShieldsTaking people
- Dartmouth Hitchcock Medical CenterLebanon, United StatesContact: Noah ShieldsTaking people
- Long Beach Veterans Administration Hospital/SCIRE ResearchLong Beach, United StatesContact: Noah ShieldsTaking people
- Baptist Cardiac and Vascular InstituteMiami, United StatesContact: Noah ShieldsTaking people
- Yale New Haven HospitalNew Haven, United StatesContact: Noah ShieldsTaking people
- North Mississippi Medical CenterTupelo, United StatesContact: Noah ShieldsTaking people
- Medstar Georgetown University HopsitalWashington D.C., United StatesContact: Noah ShieldsTaking people
About the trial
What the trial wants to find out
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon [DCB]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).
The 2 groups in the trial
- Evero DCBTreatment being tested
Treatment with Evero drug-coated balloon to apply local treatment with everolimus
- Paclitaxel-coated DCBExisting treatment, for comparison
Treatment with commercially-available drug-coated balloons to apply local treatment with paclitaxel
Treatment: Paclitaxel DCB
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Advance Evero™ 18 Everolimus-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter Versus Paclitaxel-coated Ballons in Patients With Femoropopliteal Disease (EVERO Trial)
- Plain-language title
- Everolimus-coated balloon compared with paclitaxel-coated balloons for peripheral arterial disease in the legGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 4 November 2026